Skip to content
Aminoscope
Head-to-head

Dihexa vs Semax

Not a close call but a real evidence gap: Semax has small human studies behind it, Dihexa has none, plus a growth-pathway mechanism nobody has cleared in people.

By Julian RothResearch & dataUpdated October 2026

Short answer

The evidence gap decides this one. Semax has human clinical data behind it, while Dihexa has only preclinical or minimal evidence, resting mostly on animal or lab work. Someone focused on cognition, focus and neuroprotection has trial data to go on with Semax; Dihexa, marketed for cognition and memory, is still an early-research option.

Dihexa

Preclinical / minimal

Builds synapses potently in animals, but there are no human trials — and its c-Met growth-pathway mechanism raises unanswered safety questions.

Full Dihexa evidence review

Semax

Clinical data

A BDNF-raising ACTH(4-10) analog registered as a drug in Russia — but the human evidence is small, single-country and mostly uncontrolled.

Full Semax evidence review

Dihexa vs Semax: head to head

FDA status / approved use

Dihexa

Not an approved drug; sold online as an unregulated research chemical

Semax

Registered drug in Russia; not FDA-approved
Marketed for

Dihexa

Cognition, memory

Semax

Cognition, focus, neuroprotection
Outcome areas

Dihexa

Cognitive function / memory

Semax

Cognitive function / memory
Evidence grade

Dihexa

Preclinical / minimal

Semax

Clinical data
How it works

Dihexa

Activates the HGF/c-Met system to promote new synapse formation

Semax

ACTH(4-10) analog without hormonal activity that raises brain BDNF in animal studies
Route and dosing

Dihexa

Oral pill; no established human dose

Semax

Intranasal
Headline human result

Dihexa

Not established

Semax

Not established
Strongest evidence

Dihexa

Benoist, J Pharmacol Exp Ther 2014. Little or no controlled human outcome data for the marketed useDihexa evidence reviewPubMed 25187433

Semax

Semax MND trial, Korsakov J 2007Semax evidence reviewPubMed 18379501
Key safety signal

Dihexa

No human safety data; activates c-Met, a growth pathway, raising theoretical cancer concerns

Semax

Robust and long-term human safety data are essentially absent
How it is obtained

Dihexa

Sold gray-market as a research chemical; no approved or legitimately compounded human product

Semax

Sold gray-market as a research chemical; no approved or legitimately compounded human product

marks a row where the two differ. “Not established” marks a cell the available evidence does not answer. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.

Clinical data:
Tested in humans — but investigational, discontinued, or proven only on a surrogate marker (not the marketed outcome).
Preclinical / minimal:
Evidence is largely animal, in-vitro, or anecdotal. Little or no controlled human outcome data for the marketed use.

Our verdict

These two are separated by a full rung on the evidence ladder. Semax has been given to people, though the trials are small, Russian, and mostly uncontrolled, and it is a registered drug in Russia while unapproved in the US. Dihexa has zero published human clinical trials for any indication: no efficacy data, no established dose, no human pharmacokinetics, and its synaptogenic effect appears to depend on the HGF/c-Met growth pathway, which leaves an unanswered theoretical safety question rather than a proven harm. Both are research-only in the US, and neither is FDA-approved.

Dihexa fits if

Dihexa is worth attention only as an early-stage research compound with a striking cell-culture and rodent story and an open safety question.

Semax fits if

Semax is the more defensible object of interest for anyone who wants at least some human data behind a nootropic peptide.

Dihexa vs Semax: common questions

Is either Dihexa or Semax FDA-approved?
No. Dihexa is not an approved drug; sold online as an unregulated research chemical. Semax is a registered drug in Russia; not FDA-approved.
Which has stronger human evidence, Dihexa or Semax?
Semax. It has human clinical data (key source: Semax MND trial, Korsakov J 2007), while Dihexa has only preclinical or minimal evidence (key source: Benoist, J Pharmacol Exp Ther 2014).
What are the main safety concerns with Dihexa and Semax?
Dihexa has no human safety data; activates c-Met, a growth pathway, raising theoretical cancer concerns. With Semax, robust and long-term human safety data are essentially absent.

Key studies behind each

Dihexa

  1. Wright JW, Harding JW. (2015). The development of small molecule angiotensin IV analogs to treat Alzheimer's and Parkinson's diseases. Prog Neurobiol. PubMed 25455861
  2. Benoist CC, Kawas LH, Zhu M, et al. (2014). The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-met system. J Pharmacol Exp Ther. PubMed 25187433
  3. Wright JW, Kawas LH, Harding JW. (2015). The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer's disease. J Alzheimers Dis. PubMed 25649658
  4. Ho JK, Nation DA. (2018). Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies. Neurosci Biobehav Rev. PubMed 29733881

Semax

  1. Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, et al. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Res. PubMed 16996037
  2. Tsai SJ. (2007). Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. PubMed 16996699
  3. Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, et al. (2004). The neuroprotective effects of Semax in conditions of MPTP-induced lesions of the brain dopaminergic system. Neurosci Behav Physiol. PubMed 15341218
  4. Serdiuk AV, et al. (2007). Open-label clinical trial of Semax in the treatment of motor neuron disease. Zh Nevrol Psikhiatr Im S S Korsakova. PubMed 18379501

The full evidence reviews

Where to get it

Where to get peptide therapy

Clinician-led telehealth services that prescribe compounded peptides. The specific peptides offered vary by provider — confirm Dihexa availability before ordering.

Disclosure: Aminoscope is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. Partners are listed first; a commission never changes what we write about a provider. How we make money.

Compare all 204 peptide-therapy providers →

Provider reviews we publish: RNK HealthSunlightTMatesRxPepsDirectRxSaludableRylo Health

Related comparisons